Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Xanodyne Expands U.S. Sales Force and Launches Zipsor Liquid Filled Capsules

By Pharmaceutical Processing | November 13, 2009

Xanodyne Pharmaceuticals, Inc., anintegrated specialty pharmaceutical company with both development andcommercial capabilities focused on women’s healthcare and pain management,announced today that the U.S. launch of Zipsor(TM) (diclofenac potassium)Liquid Filled Capsules, is now underway and being supported by an expanded250-member specialty sales force. In June 2009, Xanodyne received Food and Drug Administration (FDA)approval for Zipsor, a new treatment option for relief of mild to moderateacute pain in adults (18 years of age or older). With the national launch ofZipsor, Xanodyne has now successfully executed on two key elements of itsbusiness model – R&D and commercialization. Commenting on the launch, Natasha Giordano, Chief Commercial Officer,said, “The launch of Zipsor was a tremendous achievement for Xanodyne. Within90 days of receiving FDA approval, we were able to scale up our commercialorganization and secure broad distribution at retail pharmacies for theproduct.” Giordano added, “This is an exciting time for Xanodyne as we seek to gaina foothold in the pain marketplace with Zipsor. Our newly expanded team ofexperienced sales representatives enables Xanodyne to achieve a greatergeographic reach and frequency of product details to healthcare professionalsacross the United States.” Xanodyne remains committed to aggressively executing its productcommercialization strategy for its emerging product portfolio. The companyexpects FDA action soon on Lysteda(TM) (formerly XP12B), an oral tranexamicacid compound under priority review for the potential treatment of womensuffering from heavy menstrual bleeding.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE